<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02110654</url>
  </required_header>
  <id_info>
    <org_study_id>20140329</org_study_id>
    <nct_id>NCT02110654</nct_id>
  </id_info>
  <brief_title>Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery</brief_title>
  <official_title>Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery: a 9-month Randomized, Open-label, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. objectives. To compare the efficacy and the safety of mometasone furoate nasal spray
           (MFNS; Nasonex 200μg, daily) alone versus a combination with montelukast (singulair
           10mg, daily) in chronic rhinosinusitis (CRS) with asthma after functional endoscopic
           sinus surgery (FESS) for improvement the clinical control of CRS

        2. the clinical hypotheses. The investigators hypothesize that postoperative combined
           montelukast and MFNS can better improve clinical control of CRS concomitant with asthma
           after FESS compared with MFNS alone.

        3. study design This study is a 9-month randomized, open-label, controlled interventional
           study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Surgery plan

             -  Pre-operation: Patients enrolled in the study will complete assessment and specimen
                collection on the first day, then followed by 1 week drug therapy with prednisone
                (30 mg once daily) and MFNS(200ug, once daily).

             -  FESS: For patients with no surgical contraindications, FESS will be performed.
                Bilateral nasal cavities will be filled with swelling sponges postoperatively. The
                stuffing will be removed on postoperative day 2. The patients will be discharged on
                day 3 after surgery.

             -  Other treatment: All patients will receive nasal irrigation (normal saline 500 mg
                twice daily) from postoperative day 3 until day 30. Asthma will be treated as the
                guidance of professors from the Department of Respiratory Medicine in the
                investigators hospital.

        2. Drug treatment phase Three days after the surgery (FESS) described above, all patients
           will be assigned to the following two groups (30 patients each group) using random
           numbers generated by statistical software.

             -  Experimental group: Montelukast (10mg, once daily) and MFNS (200μg, once daily) for
                6 months

             -  Control group: MFNS (200μg, once daily) for 6 months

        3. Follow up After the 6-month drug treatment phase, there are still a 3-month follow-up.
           Totally, there are 5 visits after FESS surgery.

             -  Visit 1: baseline

             -  Visit 2： Day 31 post-FESS

             -  Visit 3: Day 61 post-FESS

             -  Visit 4: Day 91 post-FESS

             -  Visit 5: Day 181 post-FESS

             -  Visit 6: Day 271 post-FESS
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Decrease in Nasal symptome Visual Analogue Scale (VAS)</measure>
    <time_frame>9 months</time_frame>
    <description>nasal symptoms include general symptom, congestion, rhinorrhea, olfactory loss and headache.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Decrease in nasal endoscopy score (Lund-Kennedy score)</measure>
    <time_frame>9 months</time_frame>
    <description>Visit 1: baseline Visit 2：Day 31 post-FESS Visit 3: Day 61 post-FESS Visit 4: Day 91 post-FESS Visit 5: Day 181 post-FESS Visit 6: Day 271 post-FESS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Decrease in sinus CT score (Lund-Mackay, scoring system)</measure>
    <time_frame>6 months</time_frame>
    <description>baseline, 6 months post-FESS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Increase in Asthma Control test (ACT)</measure>
    <time_frame>9 months</time_frame>
    <description>Visit 1: baseline Visit 2：Day 31 post-FESS Visit 3: Day 61 post-FESS Visit 4: Day 91 post-FESS Visit 5: Day 181 post-FESS Visit 6: Day 271 post-FESS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>9 months</time_frame>
    <description>Visit 1: baseline Visit 2：Day 31 post-FESS Visit 3: Day 61 post-FESS Visit 4: Day 91 post-FESS Visit 5: Day 181 post-FESS Visit 6: Day 271 post-FESS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sinusitis</condition>
  <condition>Nasal Polyps</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>mometasone furoate nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mometasone furoate nasal spray,200ug qd, 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mometasone furoate nasal spray combined with montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>montelukast tablet,10mg,qd + mometasone furoate nasal spray, 200ug qd,6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <arm_group_label>mometasone furoate nasal spray</arm_group_label>
    <arm_group_label>mometasone furoate nasal spray combined with montelukast</arm_group_label>
    <other_name>singulair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate nasal spray</intervention_name>
    <arm_group_label>mometasone furoate nasal spray combined with montelukast</arm_group_label>
    <other_name>nasonex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of chronic rhinosinusitis according to European position paper of
             rhinosinusitis and nasal polyps 2007

          2. Diagnosis of asthma based on Global initiative for asthma 2012

          3. All patients should provide informed consent prior to the study and agree to follow-up
             appointments.

        Exclusion Criteria:

          1. Immunodeficiency diseases, history of head and/or facial trauma, cancer or organ
             transplant recipients.

          2. Pregnancy or lactation.

          3. Uncontrolled bronchial asthma.

          4. Acute respiratory tract infection within one month before the study.

          5. Use of leukotriene receptor antagonist within 3 months before the enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jianbo shi, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Ent department, the first affiliated hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianbo Shi, doctor</last_name>
    <phone>8602087333733</phone>
    <email>shijb@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>the first affiliated hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fenghong Chen, doctor</last_name>
      <phone>02086013560170816</phone>
      <email>chfhong@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>jianbo Shi, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Jianbo Shi</investigator_full_name>
    <investigator_title>Deputy director of ENT department</investigator_title>
  </responsible_party>
  <keyword>chronic rhinosinusitis</keyword>
  <keyword>asthma</keyword>
  <keyword>montelukast</keyword>
  <keyword>surgery</keyword>
  <keyword>treatment outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

